Science

Efficacy of PD-L1 inhibition in the treatment of endometrial cancer across molecular classes

cancer.gov

Mar 24, 2025, 16:55

Efficacy of PD-L1 inhibition in the treatment of endometrial cancer across molecular classes

A paper by Merve Kaya et al. was published in the International Journal of Gynecological Cancer, titled:

“Efficacy of PD-L1 inhibition in the treatment of endometrial cancer across molecular classes: a systematic review and meta-analysis”

Authors: Merve Kaya, Matthieu Schaddelee, Carien Creutzberg, Judith Kroep, Nanda Horeweg.

This systematic review and meta-analysis investigated the efficacy of PD-L1 inhibitors, alone or with chemotherapy, across endometrial cancer molecular classes: MMRd, p53abn, NSMP, and POLEmut.

The analysis included 7 reports on 5 clinical trials, with a focus on overall survival (OS) and progression-free survival (PFS). In patients with MMRd endometrial cancer (n = 215), adding a PD-L1 inhibitor to platinum-based chemotherapy significantly improved OS (HR 0.36, 95% CI 0.21 to 0.62) and PFS (HR 0.35, 95% CI 0.23 to 0.53).

For p53abn endometrial cancer, a significant PFS benefit was observed (HR 0.71, 95% CI 0.53 to 0.94; n = 326), but no significant OS benefit (HR 0.80, 95% CI 0.34 to 1.84; n = 135).

Conversely, in NSMP endometrial cancer, no significant benefits were seen for OS (HR 0.97, 95% CI 0.39 to 2.43; n = 242) or PFS (HR 0.80, 95% CI 0.44 to 1.44; n = 373). Data for POLEmut endometrial cancer were insufficient for meta-analysis (n = 12), but available data suggested a favorable prognosis regardless of treatment.

The study concludes that PD-L1 inhibition significantly benefits advanced or recurrent MMRd endometrial cancer.

While p53abn endometrial cancer may see potential benefit, NSMP endometrial cancer did not demonstrate significant benefits from this treatment. The molecular classification of endometrial cancer is critical for tailoring personalized PD-L1 inhibition strategies.

Read the post “Endometrioid Adenocarcinoma: What patients should know about” on oncodaily.com.

cancer Carien Creutzberg Endometrial cancer International Journal of Gynecological Cancer Judith Kroep Matthieu Schaddelee Merve Kaya Nanda Horeweg OncoDaily Oncology PD-L1 inhibition

OncoDaily and Big Whig Media Announce Partnership: Global Oncology Media Leader Joins Forces with Premier Washington, D.C. Multimedia Powerhouse

Does Vaping Cause Lung Cancer? Myths and Facts

James Van Der Beek: Battle with Colorectal Cancer and Marriage Challenges During Treatment

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care